Compound Efficacy studies
Using an in vivo model and cutting-edge technology, Nagi Bioscience delivers precise, actionable results to help researchers uncover strategies to measure the efficacy of their compounds.
Our solution enables ethical, efficient testing, providing valuable insights into the treatment efficacy. With a streamlined workflow, Nagi Bioscience accelerates the discovery and development of candidate therapeutics addressing patient diseases and ultimately improving the quality of life.
C. elegans: A gateway to drug discovery
Caenorhabditis elegans is a powerful and validated model for testing therapeutics efficacy in vivo. With a wide array of precisely quantifiable phenotypes and conserved human genetic pathways, it enables precise measurement of drug efficacy. Its short lifespan and genetic tractability support high-throughput screening and precise modeling of disease-associated proteins.
Research using C. elegans has uncovered key insights into several human diseases, advancing therapeutic discovery. In conclusion, C. elegans offers an efficient, translationally relevant platform to accelerate compound development and ultimately decreasing the time to market of therapeutics.
The Nagi Advantage
CUTTING-EDGE PLATFORM FOR HIGH-THOURGHPUT STUDIES
WORLD-CLASS EXPERTS DEDICATED TO YOU
POWERFUL IN VIVO MODEL FOR FAST AND ETHICAL TESTING
In vivo efficacy studies, at in vitro scale.
Our standardized protocols and automated workflow ensure consistent, actionable results.
To support your publications.
The much-vaunted C. elegans model delivers high translational value.
Fluorescence markers can be easily monitored and quantified for functional studies and identification of mechanism of action. Disease models can also be used (rare diseases, infectious diseases, metabolic diseases).
The advanced high-content imaging of our SydLab™ One platform enables the visualization and analysis of diverse phenotypes, supporting wider range of applications.
From research to results: Our approach
- Synchronized populations of a specific disease model C. elegans are injected into the SydLab™ One platform (day 0).
- The SydLab™ One platform tightly controls the liquid environment to which each worm is exposed, including the treatments to be tested.
- Images or videos are acquired via time-lapse microscopy at the desired frequency.
- Our AI-based algorithm detects growth, reproductive and death parameters of individual C. elegans, and provide a detailed analysis for the nematode population.
- The experiment ends at the desired time.
Readouts
- Growth dynamics and parameters
- Sexual maturity
- Egg accumulation and embryo survival
- Larvae emergence and accumulation
- Progeny size and growth
- Healthspan: Reproductive, Motility, Intestinal Atrophy.
- Lifespan: Survival.
- Fluorescence: Functional, Mechanism of Action.
Case Study: Efficacy assessment
Using Nagi Bioscience’s fully automated solution, we assessed the dose-response for the “mitochondrial unfolded protein response” activation (HSP6-GFP reporter C. elegans strain) upon exposure to different concentrations of doxycycline (Dox), 9-tert-butyl doxycycline (9-TB), or anhydrotetracycline 2 (ATc).
The SydLab™ One platform quantified the dose-dependent effects of Dox, 9-TB and ATc to the the “mitochondrial unfolded protein response”, monitored using the fluorescent bio-marker HSP6-GFP. In summary, 9-TB and ATc were more efficacious at lower doses to induce the “mitochondrial unfolded protein response” relative to Dox.
Further references
Our commitment to you and your team
At Nagi Bioscience, we are more than just a service laboratory. We are a strategic partner dedicated to your success. Our team of experts brings 50+ years of experience, a passion for innovation, and a commitment to delivering actionable insights.
Initial Discussions:
Understanding your requirements
Send us your compounds of interest
Project kick-off:
Execute with Expertise
Report delivery:
High quality reports with actionable insights